Human Growth Hormone (hGH) Market, 2025 - Key Players are Pfizer, Merck & Co. Eli Lilly and Company, Genentech, Novo Nordisk, Sandoz International, Ferring and Ipsen - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
January 24, 2018 Newswires
Share
Share
Post
Email

Human Growth Hormone (hGH) Market, 2025 – Key Players are Pfizer, Merck & Co. Eli Lilly and Company, Genentech, Novo Nordisk, Sandoz International, Ferring and Ipsen

PR Newswire

DUBLIN, Jan. 24, 2018 /PRNewswire/ --

The "Human Growth Hormone (hGH) Market Analysis By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, SGA), By Region, And Segment Forecasts, 2014 - 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global human growth hormone (hGH) market is expected to reach USD 7.1 billion by 2025

Rising cases of pituitary dysfunction and increasing use of human growth hormone are likely to drive the market in coming years.

Turner syndrome, growth hormone deficiency, Prader-Willi syndrome, idiopathic short stature, and small for gestational age (SGA) are major disorders in which growth hormone (GH) are used. Additionally, growth hormone also received an approval for other indications such as Creutzfeldt-Jakob disease, chronic kidney disease, SHOX gene haploinsufficiency, and Noonan syndrome.

Although FDA has not approved the use of hGH as anti-aging therapy, many practitioners offer injections of growth hormones at higher prices. The hGH therapy is aggressively promoted for advanced age symptoms.

hGH is anabolic as it accelerates protein synthesis and breaks down fat. Hence, athletes involved in strength demanding activities and sports are likely to use growth hormones for its anabolic effects. It is a fairly common practice among athletes and body-builders to use combination of anabolic steroids and GH for the benefits.

Further Key Findings From the Report Suggest:

  • Increasing demand for hGH due to rising growth hormone deficiency diseases and technological advancement such as recombinant DNA technology are expected to propel the market growth.
  • The growth hormone deficiency segment accounted for the highest share of the market in 2016 and is estimated to observe the fastest growth of the market. This can be attributed to increasing incidence of pituitary dysfunctioning and investment by major players for the research and development of human growth hormone drugs.
  • Turner syndrome also accounted for the significant share in the GH market. Large number of patients and effectivity of growth hormone to treat Turner's syndrome are the key reasons for the significant share in the market.
  • Geographically, North America was the largest market for GH in 2016 and is anticipated to maintain its dominance during the forecast period due to the local presence of market players, the presence of strong pipeline, and affordability of hormonal therapy.
  • Asia Pacific is estimated to witness the fastest growth during the forecast period owing to increasing healthcare expenditure, investment by market players, and large patient pool. Furthermore, increasing awareness about the therapy for short stature is likely to boost the demand for GH.
  • Some of the key players are Pfizer, Inc.; Merck & Co., Inc.; Eli Lilly and Company, Genentech, Inc., Novo Nordisk, Sandoz International GmbH, Ferring Holding SA, and Ipsen.

Key Topics Covered:

Chapter 1 Executive Summary
1.1 Market Snapshot

Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Data Analysis

Chapter 3 Human Growth Hormone Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Rising use of HGH for anti-aging and performance enhancing purposes
3.1.1.2 Increase in number of pituitary dysfunction cases
3.1.2 Market Restraint Analysis
3.1.2.1 Adverse effects
3.1.2.2 Off-label use and complex regulatory control
3.2 Penetration & Growth Prospect Mapping
3.3 Human growth hormone - SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
3.4 Industry Analysis - Porter's
3.5 Competitive Landscape: Market Position Analysis (Based on Applications, Regional Presence, and Recent Updates)

Chapter 4 Human Growth Hormone Market: Application Estimates & Trend Analysis
4.1 Human Growth Hormone: Application Analysis
4.2 Growth Hormone Deficiency
4.3 Turner syndrome
4.4 Idiopathic short stature
4.5 Prader-Willi Syndrome
4.6 Small for Gestational Age
4.7 Others

Chapter 5 Human Growth Hormone Market: Regional Estimates & Trend Analysis

Chapter 6 Competitive Landscape

  • Novo Nordisk
  • Pfizer
  • Eli Lilly
  • Sandoz International GmbH
  • Merck
  • Genentech
  • Ferring Pharmaceuticals
  • Ipsen

For more information about this report visit https://www.researchandmarkets.com/research/fh3225/human_growth?w=5

Media Contact:

Research and Markets Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/human-growth-hormone-hgh-market-2025---key-players-are-pfizer-merck--co-eli-lilly-and-company-genentech-novo-nordisk-sandoz-international-ferring-and-ipsen-300587401.html

SOURCE Research and Markets

Older

Family of trooper fatally struck by car settles lawsuits

Newer

A.M. Best Maintains Under Review With Negative Implications Status for Saudi Arabian Insurance Company B.S.C. (C)

Advisor News

  • Advisors must lead the policy risk conversation
  • Gen X more anxious than baby boomers about retirement
  • Taxing trend: How the OBBBA is breaking the standard deduction reliance
  • Why advisors can’t afford to delay succession planning
  • 6 in 10 Americans struggle with financial decisions
More Advisor News

Annuity News

  • CT commissioner: 70% of policyholders covered in PHL liquidation plan
  • ‘I get confused:’ Regulators ponder increasing illustration complexities
  • Three ways the Corebridge/Equitable merger could shake up the annuity market
  • Corebridge, Equitable merge to create potential new annuity sales king
  • LIMRA: Final retail annuity sales total $464.1 billion in 2025
More Annuity News

Health/Employee Benefits News

  • Tucson Speaks Out: April 5
  • El Rio taps experienced leader to oversee transition from North Country HealthCare to Elk Ridge
  • Red ink at Minnesota Blue Cross spells more Medicare Advantage troubles ahead
  • MEDICAID COST-SHARING LIMITATIONS AMENDED, ADVANCED
  • Legislative roundup: In a last-minute flurry, 100+ bills were sent to governor's desk; legislators back April 14
More Health/Employee Benefits News

Life Insurance News

  • WHAT THEY ARE SAYING: KATHLEEN COULOMBE JOINS ACU AS CHIEF ADVOCACY OFFICER
  • A-CAP Appoints Kirk Cullimore as President of Sentinel Security Life
  • Nationwide enters centennial year stronger than ever
  • AM Best Affirms Credit Ratings of Mutual of Omaha Insurance Company and Its Subsidiaries
  • AM Best Affirms Credit Ratings of CMB Wing Lung Insurance Company Limited
More Life Insurance News

- Presented By -

Top Read Stories

More Top Read Stories >

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Protectors Vegas Arrives Nov 9th - 11th
1,000+ attendees. 150+ speakers. Join the largest event in life & annuities this November.

An FIA Cap That Stays Locked
CapLock™ from Oceanview locks the cap at issue for 5 or 7 years. No resets. Just clarity.

Aim higher with Ascend annuities
Fixed, fixed-indexed, registered index-linked and advisory annuities to help you go above and beyond

Unlock the Future of Index-Linked Solutions
Join industry leaders shaping next-gen index strategies, distribution, and innovation.

Leveraging Underwriting Innovations
See how Pacific Life’s approach to life insurance underwriting can give you a competitive edge.

Press Releases

  • RFP #T01525
  • RFP #T01725
  • Insurate expands workers’ comp into: CA, FL, LA, NC, NJ, PA, VA
  • LifeSecure Insurance Company Announces Retirement of Brian Vestergaard, Additions to Executive Leadership
  • RFP #T02226
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.
Insurance News | InsuranceNewsNet